- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Contact us
- Thank you
Option program for the CEO and the deputy CEO
The options are valued according to Black-Scholes and gives the right to purchase one XVIVO Perfusion share for SEK 124.00 within a two year period. XVIVO Perfusion AB (publ.) is not the contracting party of this transaction since the options are issued by three large shareholders. The Board of Directors are informed of the transaction and welcomes the option program.
March 22, 2018
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on March 22, 2018.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.